Akebia Therapeutics (Akebia Therapeutics) Total Current Assets : $118.1 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Akebia Therapeutics's total current assets for the quarter that ended in Dec. 2023 was $118.1 Mil.

Akebia Therapeutics Total Current Assets Historical Data

The historical data trend for Akebia Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Total Current Assets Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

309.53

371.44

271.15

185.18

118.15

Akebia Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															185.18	120.72	118.45	109.60	118.15

Akebia Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Akebia Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	42.925	+	39.29	+	15.691	+	20.243
	=	118.1

Akebia Therapeutics's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	42.925	+	39.29	+	15.691	+	20.243
	=	118.1

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Akebia Therapeutics (NAS:AKBA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Akebia Therapeutics's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	42.925	-	272.287	+	0.75 * 39.29	+	0.5 * 15.691
=	-192.0

Akebia Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (Akebia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

AX9:Germany AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Executives

Ellen Snow	officer: SVP, CFO and Treasurer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan	officer: SVP, Chief Business Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas	officer: SVP, General Counsel, Sec.	20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman	officer: SVP, CFO and Treasurer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke	officer: SVP, Chief Medical Officer	82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler	director, officer: CEO & President	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau	officer: SVP, Chief Accounting Officer	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson	director	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham	officer: CCO	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt	director	C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen	director
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy	officer: SVP, Chief Development Officer	ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142